文献速递中药与中成药合理使用

叶酸受体靶向pH敏感聚合物胶束共载槲皮素与紫杉醇协同逆转非小细胞肺癌耐药

FA receptor-targeted pH-sensitive polymeric micelles co-encapsulating quercetin and paclitaxel for synergistic reversal of drug resistance in non-small cell lung cancer.
PubMed 文献 · Phytomedicine · 2026-08-12

本研究构建叶酸受体靶向pH响应纳米胶束FA-PM@QCT/PTX共载槲皮素与紫杉醇,在紫杉醇耐药A549/Taxol细胞及荷瘤小鼠中评价。结果显示该胶束可经叶酸受体介导内吞、酸性环境释药,联合指数0.927±0.021呈协同,并下调P-gp、抑制PI3K/Akt、促进凋亡,小鼠中位生存延长至52天且无明显全身毒性。

要点

  • FA-PM@QCT/PTX粒径166.75±4.10 nm,QCT与PTX包封率分别82.48±3.82%和84.17±1.21%。
  • PTX:QCT摩尔比约1:3时联合指数0.927±0.021,显示协同抑制耐药细胞。
  • 荷瘤小鼠中位生存延长至52天,肿瘤药物蓄积增加且无明显全身毒性。

核心结论

  • FA-PM@QCT/PTX可能为改善紫杉醇耐药非小细胞肺癌治疗提供有前景的共递送策略。

研究设计与样本

  • 构建叶酸受体靶向pH响应纳米胶束FA-PM@QCT/PTX,在紫杉醇耐药A549/Taxol细胞与A549/Taxol荷瘤小鼠模型中评价。

主要发现

  • FA-PM@QCT/PTX粒径166.75±4.10 nm,PDI 0.14±0.03,zeta电位-6.34±0.52 mV。
  • QCT包封率82.48±3.82%、载药量3.64±0.17%,PTX包封率84.17±1.21%、载药量3.59±0.11%。
  • 胶束经叶酸受体介导内吞并在酸性溶酶体条件下促进释药。
  • PTX:QCT实际摩尔比约1:3时联合指数0.927±0.021,保持协同作用。
  • FA-PM@QCT/PTX降低P-gp表达、增加胞内PTX滞留、抑制PI3K/Akt信号并促进凋亡相关通路激活。

临床怎么用

  • 该纳米共递送策略尚处临床前研究,暂不能直接转化为临床用药方案。
  • 槲皮素增敏紫杉醇的协同比例与耐药逆转机制可作为中药辅助化疗研究的参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy remains a major challenge in the effective treatment of non-small cell lung cancer (NSCLC), particularly due to chemotherapy resistance. Natural products, including Chinese herbal extracts, have shown potential for improving chemotherapy sensitivity, but their clinical application is limited by poor tumor targeting and insufficient in vivo stability. PURPOSE: This study aimed to improve PTX-based treatment against resistant NSCLC by developing a FA receptor-targeted pH-sensitive co-delivery system for QCT and PTX. STUDY DESIGN: A novel FA receptor-targeted pH-responsive nano-delivery system, FA-PM@QCT/PTX, was constructed and evaluated using PTX-resistant A549/Taxol cells and A549/Taxol tumor-bearing mouse models. METHODS: FA-PM@QCT/PTX was prepared and characterized in terms of particle size, PDI, zeta potential, encapsulation efficiency, and drug-loading content. In vitro pH-responsive release, cellular uptake, QCT/PTX synergism, cytotoxicity, apoptosis, cell-cycle distribution, P-gp expression, PI3K/Akt signaling, apoptosis-related proteins, and intracellular PTX retention were evaluated in A549/Taxol cells. Pharmacokinetics, tissue distribution, antitumor efficacy, survival benefit, and preliminary systemic safety were further assessed in A549/Taxol tumor-bearing mice. RESULTS: FA-PM@QCT/PTX showed a particle size of 166.75 ± 4.10 nm, a PDI of 0.14 ± 0.03, and a zeta potential of -6.34 ± 0.52 mV. The encapsulation efficiencies were 82.48 ± 3.82 % for QCT and 84.17 ± 1.21 % for PTX, with drug-loading contents of 3.64 ± 0.17 % and 3.59 ± 0.11 %, respectively. The self-assembled micelles could be internalized by tumor cells via FA receptor-mediated uptake and promote drug release under acidic lysosomal conditions. Chou-Talalay analysis showed that QCT enhanced the inhibitory effect of PTX on A549/Taxol cells, and the actual PTX:QCT molar ratio in FA-PM@QCT/PTX was approximately 1:3, which remained synergistic with a combination index (CI) value of 0.927 ± 0.021. Mechanistically, FA-PM@QCT/PTX reduced P-gp expression, enhanced intracellular PTX retention, suppressed PI3K/Akt signaling, and promoted apoptosis-related pathway activation. In vivo, FA-PM@QCT/PTX improved tumor drug accumulation and prolonged the median survival of A549/Taxol tumor-bearing mice to 52 days without obvious systemic toxicity. CONCLUSIONS: These results suggest that FA-PM@QCT/PTX may provide a promising co-delivery strategy for improving PTX-based treatment against resistant NSCLC.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Shi H, Li F, Wang M, et al. FA receptor-targeted pH-sensitive polymeric micelles co-encapsulating quercetin and paclitaxel for synergistic reversal of drug resistance in non-small cell lung cancer. Phytomedicine. 2026. PMID: 42607382. doi:10.1016/j.phymed.2026.158710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。